atai Life Sciences (NASDAQ: ATAI) (atai), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, has announced the pricing of a registered underwritten offering of 23,725,000 common shares, at a price of US$5.48 per share. atai has granted the underwriters a 30-day option to purchase up to an additional 3,558,750 common shares at the public offering price, less the underwriting discount. All common shares to be sold in the offering will be sold by atai. The offering is expected to close on October 20, 2025, subject to customary closing conditions.
Latham & Watkins represents atai Life Sciences in the offering with a corporate team led by partner Nathan Ajiashvili, with associates Kaj Nielsen, Adam Picker, and Elana Cates. Advice was also provided on public company representation matters by counsel Irina Yevmenenko, with associate Catriela Cohen.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.